GXE.F Galapagos NV

Healthcare Biotechnology Frankfurt Exchange
30.52 EUR
Close of Nov 13, 2026
22.32 30.32
Market cap
EUR 2.01B
P/E
3.4x
P/B
0.60x
ROE
1.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GXE.F undervalued?

Graham number

The Graham number of Galapagos NV cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Galapagos NV fundamental analysis

No fundamental analysis for Galapagos NV yet.

Galapagos NV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Galapagos NV

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product ca…

Full company profile